Interferon alpha in the therapy of CML

M Talpaz; H Kantarjian; R Kurzrock; J U Gutterman

doi:10.1111/j.1365-2141.1991.tb08117.x

Interferon alpha in the therapy of CML

Br J Haematol. 1991 Oct:79 Suppl 1:38-41. doi: 10.1111/j.1365-2141.1991.tb08117.x.

Authors

M Talpaz¹, H Kantarjian, R Kurzrock, J U Gutterman

Affiliation

¹ Department of Clinical Immunology and Biological Therapy, University of Texas Cancer Center, M.D. Anderson Hospital, Houston.

PMID: 1931707
DOI: 10.1111/j.1365-2141.1991.tb08117.x

Abstract

This paper summarizes the experience with interferon alpha (IFN alpha) as single-agent therapy and in combination gathered at M.D. Anderson Cancer Center. It also covers some of the laboratory research associated with these clinical studies.

MeSH terms

Combined Modality Therapy
Cytarabine / therapeutic use
Humans
Interferon alpha-2
Interferon-alpha / therapeutic use*
Interferon-gamma / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Recombinant Proteins

Substances

Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Cytarabine
Interferon-gamma